Vitalant

Vitalant Research Institute, the research and specialized services division of Vitalant and the nation's largest independent nonprofit blood services provider, operates as a prime contractor delivering blood collection, processing, testing, and transfusion medicine research services to federal healthcare agencies across the United States. The organization competes predominantly in open, unrestricted federal procurement with no set-aside designations, serving approximately 900 hospitals across 28 states with a headquarters in Scottsdale, Arizona.

Vitalant Research Institute's federal capability footprint centers on blood product supply, laboratory testing, and transfusion medicine research. Recent prime contract work spans blood products for the Indian Health Service's Phoenix Area Office and tribal health facilities ($3.05 million IDIQ through August 2027); blood and blood products for the Department of Veterans Affairs across multiple Integrated Service Networks with individual single-award IDIQs valued at $2.0 million to $7.0 million; the Transfusion-Transmissible Infections Monitoring System (TTIMS) contract with the Food and Drug Administration ($9.99 million definitive contract through September 2029); and REDS-IV-P transfusion research programs with the National Heart, Lung, and Blood Institute ($2.1 million to $2.7 million delivery orders). The organization also delivers therapeutic apheresis services, heparin testing, and specialized reference laboratory work to VA facilities and military medical centers including David Grant Medical Center at Travis Air Force Base ($750 thousand purchase order through September 2026).

Customer concentration is distributed across federal healthcare and research agencies. The top five funding agencies account for approximately 70% of combined potential value, led by the National Heart, Lung, and Blood Institute ($119.7 million across 35 awards), the Food and Drug Administration ($92.5 million across 6 awards), Veterans Integrated Service Network 22 ($53.1 million across 76 awards), Veterans Integrated Service Network 21 ($53.1 million across 67 awards), and the Indian Health Service ($49.8 million across 486 awards). Award count and dollar concentration diverge materially: IHS drives volume with 486 awards but moderate per-order value, while NHLBI anchors research funding with fewer awards at high individual magnitude. The Defense Health Agency and Air Combat Command contribute military medical facility support.

Vitalant Research Institute holds multiple single-award IDIQs and blanket purchase agreements across the VA system and Indian Health Service. The vendor maintains active indefinite delivery contracts with VISN 21 ($2.0 million through September 2030), VISN 22 ($7.0 million through September 2029), VISN 23 ($1.14 million through September 2026), VISN 4 for heparin testing ($53 thousand through December 2030), and a $4.9 million BPA with VISN 19 for human blood and blood products through September 2028. The Indian Health Service vehicle valued at $3.05 million (through August 2027) anchors tribal healthcare supply. A $9 million IHS indefinite delivery contract awarded July 2026 for blood supply services to Phoenix Area Office facilities carries four delivery orders totaling $1.23 million. The FDA's TTIMS contract represents the largest research vehicle. Top parent vehicles by task-order count include legacy IHS IDIQs (75H70621D00011 with 35 task orders; 75H71020D00002 with 28 task orders) and blanket purchase agreements across multiple VISNs.

Activity has remained steady at 40–52 awards per year over the past five years, with 14 awards recorded in 2026 year-to-date. Thirty-six awards face ultimate completion within the next twenty-four months, carrying combined potential value of $16.4 million and representing near-term recompete exposure. Recent activity shows continued growth in research grant funding from NIH institutes; the organization received $262.5 thousand and $1.32 million Project Grants from the National Heart, Lung, and Blood Institute in September 2025 for transfusion-related lung injury research and platelet bioenergetics studies, respectively, plus a Cooperative Agreement from the National Center for Emerging and Zoonotic Infectious Diseases for respiratory virus surveillance in blood donors (awarded September 2024, through August 2029).

SCI-reported invoiced revenue on federal service contracts above $150 thousand totaled $47.3 million across FY2022–FY2024 ($18.8 million in FY2022, $17.2 million in FY2023, $11.3 million in FY2024), supporting roughly 58–67 FTEs annually on prime contracts. Government-paid hourly rates on prime SCI contracts ranged from $20.70/hr at the 10th percentile to $300.75/hr at the 90th percentile, with a median of $138.06/hr, indicating mixed labor mix spanning low-skilled phlebotomy and logistics through high-skilled research and medical direction. Across prime SCI-reportable contracts, subcontractors performed approximately 40% of contractor hours, drawing from a roster of 51 named subcontractors. The vendor acts as a prime across most of its federal work (98% of awards), with limited subcontractor positioning.

Named subsidiaries include Blood Systems Inc., Central Blood Bank, Lifestream Blood Bank, The Institute For Transfusion Medicine, and ITXM Diagnostics Inc., reflecting Vitalant's multi-region blood banking and laboratory diagnostic footprint. Federal grant sub-awards show partnerships with Emory University, University of Maryland Baltimore, Boston College, University of California San Francisco, Stanford University, The Wistar Institute, and others on NIH-funded HIV persistence, cardiovascular disease in HIV-positive populations, and viral infection research. Prime contractors Vitalant subcontracts under include Cincinnati University (red blood cell kinetics validation work) and academic research institutions on collaborative awards. The vendor's research program is materially integrated with federal health and biomedical research priorities, positioning it as both a service supplier and research institution within the federal blood and transfusion medicine ecosystem.